These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 8257443

  • 1. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.
    Ellis V, Danø K.
    Biochem J; 1993 Dec 01; 296 ( Pt 2)(Pt 2):505-10. PubMed ID: 8257443
    [Abstract] [Full Text] [Related]

  • 2. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V.
    J Biol Chem; 1996 Jun 21; 271(25):14779-84. PubMed ID: 8662951
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC.
    Eur J Biochem; 1997 Apr 15; 245(2):316-23. PubMed ID: 9151959
    [Abstract] [Full Text] [Related]

  • 5. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.
    Biol Chem; 2001 Aug 15; 382(8):1197-205. PubMed ID: 11592401
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
    Behrendt N, Danø K.
    FEBS Lett; 1996 Sep 09; 393(1):31-6. PubMed ID: 8804418
    [Abstract] [Full Text] [Related]

  • 8. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S, Lockett J, Meng Y, Biliran H, Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, Cher ML, Sheng S.
    Cancer Res; 2006 Apr 15; 66(8):4173-81. PubMed ID: 16618739
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE, Saunders DN, Ranson M.
    Breast Cancer Res; 2007 Apr 15; 9(1):R14. PubMed ID: 17257442
    [Abstract] [Full Text] [Related]

  • 11. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin.
    Behrendt N, Rønne E, Danø K.
    J Biol Chem; 1993 Mar 15; 268(8):5985-9. PubMed ID: 8383683
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V, Mukhina S, Köhler E, Resink TJ, Erne P, Tkachuk VA.
    Mol Cell Biochem; 1999 May 15; 195(1-2):199-206. PubMed ID: 10395084
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J, Jögi A, Lund IK, Rønø B, Rasch MG, Gårdsvoll H, Lund LR, Ploug M, Rømer J, Danø K, Høyer-Hansen G.
    Thromb Haemost; 2007 Jun 15; 97(6):1013-22. PubMed ID: 17549305
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
    Reinartz J, Link J, Todd RF, Kramer MD.
    Exp Cell Res; 1994 Oct 15; 214(2):486-98. PubMed ID: 7925643
    [Abstract] [Full Text] [Related]

  • 18. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
    Le DM, Besson A, Fogg DK, Choi KS, Waisman DM, Goodyer CG, Rewcastle B, Yong VW.
    J Neurosci; 2003 May 15; 23(10):4034-43. PubMed ID: 12764090
    [Abstract] [Full Text] [Related]

  • 19. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
    Behrendt N, List K, Andreasen PA, Danø K.
    Biochem J; 2003 Apr 15; 371(Pt 2):277-87. PubMed ID: 12534347
    [Abstract] [Full Text] [Related]

  • 20. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF.
    Cancer Res; 2000 Jan 15; 60(2):342-9. PubMed ID: 10667586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.